Itolizumab is an anti-cd6 mAb, approved in India f
Post# of 148175
(Total Views: 837)
Posted On: 11/19/2020 9:06:41 AM
Itolizumab is an anti-cd6 mAb, approved in India for plaque psoriasis.
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519855/
“Itolizumab, by virtue of its immunomodulation and its trafficking to the inflammation site, spares Tregs and conserves the antiviral response. The signature cytokines that are reduced include IL-2, IFNγ and TNFα through Th-1 pathway and IL-17, IL-6 and TNFα through Th-17 pathway. This is in contrast to biologics like tocilizumab or anakinra which block only the specific cytokines released downstream“
However
“ In the absence of direct head-to-head comparisons, any comments on the safety profile of the drug and its efficacy cannot be made definitively. As the data is too little for the results to be regarded as promising, we exercise caution over the use of this understudied drug and urge clinicians to avoid indiscriminate use based on unwarranted speculations. While the scientific community demands evidence-based recommendations, we need to bear in mind that quality and quantity of evidence are a necessary prerequisite in framing guidelines, even in the most pressing times. As the oath goes, “First, do no harm”.
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519855/
“Itolizumab, by virtue of its immunomodulation and its trafficking to the inflammation site, spares Tregs and conserves the antiviral response. The signature cytokines that are reduced include IL-2, IFNγ and TNFα through Th-1 pathway and IL-17, IL-6 and TNFα through Th-17 pathway. This is in contrast to biologics like tocilizumab or anakinra which block only the specific cytokines released downstream“
However
“ In the absence of direct head-to-head comparisons, any comments on the safety profile of the drug and its efficacy cannot be made definitively. As the data is too little for the results to be regarded as promising, we exercise caution over the use of this understudied drug and urge clinicians to avoid indiscriminate use based on unwarranted speculations. While the scientific community demands evidence-based recommendations, we need to bear in mind that quality and quantity of evidence are a necessary prerequisite in framing guidelines, even in the most pressing times. As the oath goes, “First, do no harm”.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼